CA2316277A1 - Tablet for instant and prolonged release of one or more active substances - Google Patents

Tablet for instant and prolonged release of one or more active substances Download PDF

Info

Publication number
CA2316277A1
CA2316277A1 CA002316277A CA2316277A CA2316277A1 CA 2316277 A1 CA2316277 A1 CA 2316277A1 CA 002316277 A CA002316277 A CA 002316277A CA 2316277 A CA2316277 A CA 2316277A CA 2316277 A1 CA2316277 A1 CA 2316277A1
Authority
CA
Canada
Prior art keywords
instant
active substances
tablet
prolonged release
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002316277A
Other languages
French (fr)
Other versions
CA2316277C (en
Inventor
Olivier Saslawski
Laurence Orlando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent Gesellschaft Mit Beschraenkter Haftung
Olivier Saslawski
Laurence Orlando
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gesellschaft Mit Beschraenkter Haftung, Olivier Saslawski, Laurence Orlando filed Critical Merck Patent Gesellschaft Mit Beschraenkter Haftung
Publication of CA2316277A1 publication Critical patent/CA2316277A1/en
Application granted granted Critical
Publication of CA2316277C publication Critical patent/CA2316277C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The invention relates to a multilayer tablet for the instant and then prolonged release of active substances comprising at least two superposed layers, characterized in that: a first outer layer is composed of a mixture of excipients and of a first active substance, the said first layer allowing immediate release of the said first active substance; a second layer, arranged in contact with the said first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.
CA002316277A 1997-12-23 1998-12-11 Tablet for instant and prolonged release of one or more active substances Expired - Fee Related CA2316277C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9716402A FR2772615B1 (en) 1997-12-23 1997-12-23 MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
FR97/16402 1997-12-23
PCT/EP1998/008100 WO1999033448A1 (en) 1997-12-23 1998-12-11 Tablet for instant and prolonged release of one or more active substances

Publications (2)

Publication Number Publication Date
CA2316277A1 true CA2316277A1 (en) 1999-07-08
CA2316277C CA2316277C (en) 2008-07-08

Family

ID=9515042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002316277A Expired - Fee Related CA2316277C (en) 1997-12-23 1998-12-11 Tablet for instant and prolonged release of one or more active substances

Country Status (24)

Country Link
US (1) US6372255B1 (en)
EP (1) EP1041972B1 (en)
JP (1) JP4451563B2 (en)
KR (1) KR100574207B1 (en)
CN (1) CN1163220C (en)
AR (1) AR017897A1 (en)
AT (1) ATE223207T1 (en)
AU (1) AU743195B2 (en)
BR (1) BR9814345A (en)
CA (1) CA2316277C (en)
CZ (1) CZ291884B6 (en)
DE (1) DE69807747T2 (en)
DK (1) DK1041972T3 (en)
ES (1) ES2182397T3 (en)
FR (1) FR2772615B1 (en)
HU (1) HU226069B1 (en)
ID (1) ID26313A (en)
NO (1) NO20003289L (en)
PT (1) PT1041972E (en)
RU (1) RU2212885C2 (en)
SK (1) SK283236B6 (en)
UA (1) UA55503C2 (en)
WO (1) WO1999033448A1 (en)
ZA (1) ZA9811799B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029290A1 (en) * 2014-08-29 2016-03-03 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9375404B2 (en) 2012-02-22 2016-06-28 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9439920B2 (en) 2013-07-22 2016-09-13 Duchesnay Inc. Composition for the management of nausea and vomiting
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US10028941B2 (en) 2013-07-22 2018-07-24 Duchesnay Inc. Composition for the management of nausea and vomiting

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
DE19821625C1 (en) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmaceutical preparation
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1210079A2 (en) * 1999-08-20 2002-06-05 Ferrosan A/S A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
AU783656B2 (en) * 1999-09-02 2005-11-24 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
WO2001022791A2 (en) * 1999-09-28 2001-04-05 Panacea Biotec Limited Controlled release compositions comprising nimesulide
EP1138330A1 (en) * 1999-12-23 2001-10-04 Warner-Lambert Company Combination of trimebutine with an opioid analgesic
BR0007360A (en) * 1999-12-23 2001-08-14 Johnson & Johnson Controlled release composition
ATE340563T1 (en) 2000-02-04 2006-10-15 Depomed Inc SHELL AND CORE TYPE DOSAGE FORM WITH A RELEASE OF ACTIVE INGREDIENTS APPROACHING TO THE ZERO ORDER
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
ES2220789T3 (en) * 2000-10-30 2004-12-16 Lupin Limited COMPOSITION OF CEFUROXIMA AXETILO SLOW RELEASE THAT DISAPPEARS RAPIDLY.
KR100778835B1 (en) * 2000-12-28 2007-11-22 엘지.필립스 엘시디 주식회사 Method of Manufacturing of Liquid Crystal Display
KR100685945B1 (en) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 Liquid crystal display and manufacturing method of the same
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
AU2002256092C1 (en) * 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
CA2343949A1 (en) * 2001-04-12 2002-10-12 Bernard Charles Sherman Benazepril hydrochloride tablet formulations
SE0101379D0 (en) 2001-04-18 2001-04-18 Diabact Ab Composition that inhibits gastric acid secretion
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20040043066A1 (en) * 2001-10-29 2004-03-04 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
AR040682A1 (en) 2002-07-25 2005-04-13 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
AR040588A1 (en) * 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
KR101363679B1 (en) * 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 Pharmaceutical tablet
SE0203065D0 (en) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
MXPA02010828A (en) * 2002-11-04 2004-07-16 Leopoldo Espinosa Abdala Pharmaceutical composition in capsules comprising a non-steroidal anti-inflammatory and an opiate analgesic for handling pain.
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
DE602004015246D1 (en) * 2003-02-11 2008-09-04 Alza Corp METHOD AND DOSAGE FORMS WITH MODIFIED LAYERING GEOMETRY
FR2851734B1 (en) * 2003-02-28 2006-06-09 Galenix Innovations PROCESS FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION IN THE FORM OF TABLETS CONTAINING A FIBRATE AND COMPRESSES OBTAINED BY THE PROCESS
AU2004222339A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
PL1615622T3 (en) 2003-04-07 2012-12-31 Supernus Pharmaceuticals Inc Once daily formulations of doxycyclines
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US6863830B1 (en) * 2003-08-21 2005-03-08 Biolab Services, Inc. Dual layer tablet, method of making and use thereof
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
MXPA06003453A (en) * 2003-09-26 2006-08-31 Johnson & Johnson Oros push-stick for controlled delivery of active agents.
NZ546148A (en) 2003-09-26 2009-05-31 Alza Corp Drug coating providing high drug loading and methods for providing the same
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050084531A1 (en) * 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
RS20060413A (en) * 2004-01-06 2008-11-28 Panacea Biotec Ltd., Non-disintegrating oral solid composition of high dose of water soluble drugs
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2005099672A1 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
SI1591109T1 (en) * 2004-04-30 2008-10-31 Topotarget Germany Ag Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
FR2873113B1 (en) * 2004-07-19 2007-06-15 Eurotab Sa COMPACT SOLID BILOUCHE PRODUCT FOR WATER PURIFICATION
US20060020007A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and biotin and their pharmaceutical uses
JP4785847B2 (en) * 2004-08-13 2011-10-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tablet formulation with extended release comprising pramipexole or a pharmaceutically acceptable salt thereof, process for its production and use thereof
AU2005282784B2 (en) 2004-09-01 2008-06-19 Euro-Celtique S.A. Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
WO2006081347A2 (en) * 2005-01-26 2006-08-03 Elan Pharma International Limited Controlled release compositions comprising an antipsychotic agent
DE102005019458A1 (en) 2005-04-25 2006-10-26 Grünenthal GmbH Composition, useful in the preparation of pellets and the multi-particular-presentation form, comprises cefuroximaxetil and carrageenan of the group of lambda carrageenan, tau carrageenan and kappa carrageenan
CA2604617C (en) * 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
ATE480229T1 (en) * 2005-05-24 2010-09-15 Flamel Tech Sa ORAL PHARMACEUTICAL COMPOSITION FOR TREATING A COX-2-MEDIATED DISEASE
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
KR101655455B1 (en) * 2005-09-09 2016-09-07 안젤리니 라보팜 엘엘씨 Trazodone composition for once a day administration
AU2005336956A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
DE102005048293A1 (en) * 2005-10-08 2007-04-12 Sanofi-Aventis Deutschland Gmbh Retard formulation for pralnacasan
WO2007065559A1 (en) * 2005-11-18 2007-06-14 Synthon B.V. Zolpidem tablets
DE602006018529D1 (en) 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft MULTILAYER TABLET WITH TRIPLE RELEASE COMBINATION
CZ300698B6 (en) * 2006-06-16 2009-07-22 Zentiva, A. S. Metformin-containing tablet
FR2906801B1 (en) * 2006-10-05 2008-12-12 Eurotab Sa SOLID COMPACT WATER POTABILIZING BILOUD SOLID PRODUCT AND PROCESS FOR PREPARING THE SAME.
US8642083B2 (en) 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
US8394845B2 (en) 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
EP2120945A1 (en) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamine combination
US20100098757A1 (en) * 2007-03-15 2010-04-22 Toyo Boseki Kabushiki Kaisha Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa
WO2008142627A2 (en) * 2007-05-17 2008-11-27 Ranbaxy Laboratories Limited Multilayered modified release formulation comprising amoxicillin and clavulanate
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
MX2009013384A (en) * 2007-06-08 2010-01-25 Addrenex Pharmaceuticals Inc Extended release formulation and method of treating adrenergic dysregulation.
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
AU2008314454A1 (en) * 2007-10-16 2009-04-23 Labopharm (Barbados) Limited Bilayer composition for the sustained release of acetaminophen and tramadol
JP5651818B2 (en) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド Controlled release formulation to prevent misuse
FR2927965B1 (en) * 2008-02-22 2010-06-04 Valeo Materiaux De Friction Sa METHOD FOR MANUFACTURING FRICTION MATERIAL AND IN PARTICULAR CLUTCH FRICTION CROWN
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
JP2009256237A (en) * 2008-04-16 2009-11-05 Daiichi Sankyo Healthcare Co Ltd Solid preparation
MX340249B (en) 2008-08-15 2016-07-01 Depomed Inc Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders.
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
CN102245171A (en) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 Slow-release particle and a production method therefor
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
PL2389166T3 (en) * 2009-01-23 2013-04-30 Hoffmann La Roche Pharmaceutical composition comprising aleglitazar
KR101050076B1 (en) * 2009-02-04 2011-07-19 한국유나이티드제약 주식회사 Compositions of Oral Formulations Containing Controlled Release Aceclofenac and Methods for Making the Same
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
CN102883601A (en) 2009-12-02 2013-01-16 阿达玛斯医药公司 Amantadine compositions and methods of use
WO2011080716A2 (en) 2010-01-04 2011-07-07 Wockhardt Limited Pharmaceutical composition for modified delivery of actives
US20110274751A1 (en) * 2010-05-04 2011-11-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Trimetazidine formulation with different release profiles
AR084698A1 (en) * 2010-06-22 2013-06-05 Twi Pharmaceuticals Inc COMPOSITIONS OF CONTROLLED RELEASE WITH REDUCED FOOD EFFECT, REDUCED INTERACTION BETWEEN PHARMACO AND FOOD
CN102727496A (en) * 2011-04-12 2012-10-17 上海双健现代药物技术咨询有限公司 Compound antituberculosis drug oral solid preparation and its preparation method
WO2013063078A1 (en) 2011-10-28 2013-05-02 Vitalis Llc Anti-flush compositions
BR112014016085A8 (en) 2011-12-28 2017-07-04 Pozen Inc Enhanced compositions and methods for delivery of omeprazole plus acetylsalicylic acid
PL2809305T3 (en) * 2012-01-31 2016-03-31 Sanovel Ilac Sanayi Ve Ticaret As Bilayer tablet formulations of flurbiprofen and glucosamin
EP2817001A1 (en) * 2012-02-20 2014-12-31 Lupin Limited Bilayer tablet of dronedarone
US20140072671A1 (en) * 2012-06-29 2014-03-13 Adam Auerbach Multi-component oral delivery systems and uses thereof
WO2014075155A1 (en) * 2012-11-14 2014-05-22 Diffucap Chemobras Química E Farmacêutica Ltda Pharmaceutical combination containing an analgesic agent and an antispasmodic agent
KR102237799B1 (en) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. Compositions containing a biologically active material and a non-ordered inorganic oxide
RU2521572C1 (en) * 2012-12-21 2014-06-27 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) Cocrystalline form of fenbufen
KR20150126383A (en) * 2013-03-12 2015-11-11 바이오히트 오와이제이 Composition for oral administration for binding aldehydes in the gastrointestinal tract
KR101778106B1 (en) 2013-04-29 2017-09-13 끌라리앙 프로딕숑 (프랑스) 에스.아.에스. Cap for a container
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2015027303A1 (en) * 2013-08-28 2015-03-05 Diffucap Chemobras Quimica E Farmaceutica Ltda Method for manufacturing a pharmaceutical combination containing an analgesic agent and an antispasmodic agent and pharmaceutical combination
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
CA2936741C (en) * 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10413403B2 (en) * 2015-07-14 2019-09-17 Boston Scientific Scimed, Inc. Prosthetic heart valve including self-reinforced composite leaflets
MX2018000939A (en) * 2015-07-23 2018-06-07 Athena Drug Delivery Solutions Pvt Ltd Zolpidem composition and process for preparing the same.
AU2018320946A1 (en) 2017-08-24 2020-04-16 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US11819482B2 (en) 2017-08-29 2023-11-21 Conrig Pharma Aps Composition comprising suplatast tosilate
US20230040902A1 (en) * 2019-12-19 2023-02-09 Celltrion Inc. Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof
CN114432300B (en) * 2022-02-16 2023-08-01 平顶山市第二人民医院 Pharmaceutical composition containing bisoprolol and enalapril and process thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5911563B2 (en) * 1980-02-27 1984-03-16 日本原子力研究所 Method for manufacturing multilayer sustained release composites
IT1206166B (en) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti DEVICE FOR RELEASING A SUBSTANCE IN A DISSOLUTION FLUID WITH ZERO ORDER KINETICS AND PROCEDURE FOR ITS PREPARATION
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
FR2645152B1 (en) * 1989-03-30 1991-05-31 Lipha 3H-PTERIDINONES-4, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM
JP5170723B2 (en) * 1997-01-10 2013-03-27 アボット・ラボラトリーズ Tablets for controlled release of active agents

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375404B2 (en) 2012-02-22 2016-06-28 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9937132B2 (en) 2012-02-22 2018-04-10 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9439920B2 (en) 2013-07-22 2016-09-13 Duchesnay Inc. Composition for the management of nausea and vomiting
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
US10028941B2 (en) 2013-07-22 2018-07-24 Duchesnay Inc. Composition for the management of nausea and vomiting
WO2016029290A1 (en) * 2014-08-29 2016-03-03 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EA032671B1 (en) * 2014-08-29 2019-06-28 Дюшене Инк. Solid oral dosage form comprising doxylamine and pyridoxine and/or salts thereof

Also Published As

Publication number Publication date
CA2316277C (en) 2008-07-08
DE69807747T2 (en) 2003-06-12
HUP0100406A2 (en) 2001-08-28
CN1163220C (en) 2004-08-25
SK9322000A3 (en) 2001-04-09
KR20010033532A (en) 2001-04-25
AR017897A1 (en) 2001-10-24
FR2772615B1 (en) 2002-06-14
NO20003289D0 (en) 2000-06-22
SK283236B6 (en) 2003-04-01
EP1041972A1 (en) 2000-10-11
ATE223207T1 (en) 2002-09-15
CN1283110A (en) 2001-02-07
KR100574207B1 (en) 2006-04-27
ES2182397T3 (en) 2003-03-01
DK1041972T3 (en) 2003-01-06
BR9814345A (en) 2000-10-03
HU226069B1 (en) 2008-04-28
ZA9811799B (en) 1999-06-22
EP1041972B1 (en) 2002-09-04
PT1041972E (en) 2003-01-31
AU2160699A (en) 1999-07-19
FR2772615A1 (en) 1999-06-25
WO1999033448A1 (en) 1999-07-08
JP4451563B2 (en) 2010-04-14
CZ20002332A3 (en) 2000-10-11
NO20003289L (en) 2000-08-22
AU743195B2 (en) 2002-01-24
UA55503C2 (en) 2003-04-15
JP2001527034A (en) 2001-12-25
US6372255B1 (en) 2002-04-16
DE69807747D1 (en) 2002-10-10
ID26313A (en) 2000-12-14
CZ291884B6 (en) 2003-06-18
RU2212885C2 (en) 2003-09-27

Similar Documents

Publication Publication Date Title
CA2316277A1 (en) Tablet for instant and prolonged release of one or more active substances
CA2196840A1 (en) Pharmaceutical tablet suitable to deliver the active substance in subsequent and predeterminable times
CA2347105A1 (en) Controlled-release pharmaceutical composition with gastric residence
CA2124553A1 (en) Pharmaceutical Tablet Capable of Releasing the Active Ingredients Contained Therein at Subsequent Times
CA2213987A1 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
CA2391393A1 (en) Film preparation for biphasic release of pharmacologically active or other substances
CA2182508A1 (en) Abuse resistant tablets
NZ336462A (en) Pharmaceutical composition of fenofibrate with high biological availability
CA2145513A1 (en) Pharmaceutical Tablet Capable of Liberating One or More Drugs at Different Release Rates
CA2161004A1 (en) Active ingredient patch
IT1265240B1 (en) CONTROLLED RELEASE PHARMACEUTICAL TABLET, LENTICULAR
CA2409292A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2235520A1 (en) Bioadhesive tablets
CA2377167A1 (en) Multilayered tablet for administration of a fixed combination of tramadol and diclofenac
CA2131495A1 (en) Double-layered oxcarbazepine tablets
CA2298659A1 (en) Fast-acting analgesic
AU7782794A (en) Transdermal therapeutic system with acetylsalicylic acid as active substance
TW279799B (en)
WO1999014078A3 (en) Non-blocking filter
MY113919A (en) Layered tablet for the controlled release of active substances
CA2185242A1 (en) Sustained release tablet containing diclofenac-na
CA2260845A1 (en) Oral preparation containing at least one active pharmaceutical substance in a matrix capable of swelling in an aqueous medium
EP1020182A3 (en) A two-layer pharmaceutical tablet comprising an nsaid and misoprostol
TH52209A (en) Rigid tablet-type formulation with controlled release for immediate rapid release of one or more substances. And then the release was lengthened.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151211